false
0001710072
0001710072
2024-08-08
2024-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 8, 2024
Edgewise Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40236 |
|
82-1725586 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.) |
1715
38th St.
Boulder,
CO 80301
(Address of principal executive offices) (Zip Code)
(720)
262-7002
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
EWTX |
|
The
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02 | Results of Operations and Financial Condition. |
On August 8, 2024,
Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2024.
The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information
furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a filing.
Item 9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
EDGEWISE
THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/
R. Michael Carruthers |
|
|
R.
Michael Carruthers |
|
|
Chief
Financial Officer |
Date: August 8, 2024
Exhibit 99.1
Edgewise Therapeutics
Reports Second Quarter 2024 Financial Results and Recent Business Highlights
– Completed
Phase 1 SAD and MAD trial of EDG-7500 in healthy volunteers; Dosing patients in Phase 2 CIRRUS-HCM trial of EDG-7500 in individuals with
oHCM –
– Continued
to advance GRAND CANYON global pivotal cohort of sevasemten in adults with Becker –
– Advanced
Phase 2 LYNX and FOX trials of sevasemten in children with Duchenne –
Boulder, Colo., (August 8,
2024) – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported
financial results for the second quarter of 2024 and recent business highlights.
“We continue to make strong progress
on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “We
look forward to sharing important updates on both our EDG-7500 and sevasemten programs over the coming months.”
Recent Highlights
Cardiovascular Program / EDG-7500
EDG-7500 is a novel oral, selective,
cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated
with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. Preclinical data in models of both obstructive and
non-obstructive HCM suggest the ability to drive a beneficial response at a low risk of decreasing left ventricular ejection fraction
below normal at all doses tested. Based on EDG-7500’s self-limiting effect on systolic contraction observed in preclinical models,
the Company plans to investigate fixed-dose regimens of EDG-7500, thus potentially avoiding intensive safety monitoring of patients.
Phase 1 Trial of EDG-7500: During
the quarter, the Company completed the randomized, placebo-controlled, single and multiple ascending dose Phase 1 trial evaluating safety,
tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy adults.
Phase
2 CIRRUS-HCM trial of EDG-7500: The Company continues to enroll CIRRUS-HCM, a multi-center, two-part, open-label trial of EDG-7500
in patients with obstructive HCM at up to 20 clinical sites in the U.S. The trial will evaluate the safety, tolerability, PK and PD of
EDG-7500 in up to 55 participants. Participants enrolled in this trial will receive EDG-7500 as a single oral dose (Part A) and
have the option to receive multiple oral doses for 28 days (Part B). Part B of the trial will also enroll non-obstructive HCM
patients who will be studied over 28-days. The Company is on track to present topline data of EDG-7500 from the Phase 1 trial in healthy
volunteers and from the single dose arm of CIRRUS-HCM (Part A) in patients with obstructive HCM (three cohorts across different
doses) in September. To learn more about these trials visit clinicaltrials.gov, NCT06011317 (Phase 1) and NCT06347159 (Phase
2).
Muscular Dystrophy Program / sevasemten
Becker Muscular Dystrophy (Becker)
Sevasemten is an orally administered
small molecule designed to prevent contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are
currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder with significant unmet
need.
CANYON Phase 2 placebo-controlled
trial in adults with Becker: CANYON, the largest interventional Becker trial to date, includes 40 adults and 29 adolescents with
a sevasemten treatment period of 12 months. The primary endpoint of CANYON is change in creatine kinase (CK) over the treatment period
with additional measures collected, including North Star Ambulatory Assessment (NSAA), 100-meter timed test, biomarkers of muscle damage
and MRI. The Company expects to report CANYON data in the fourth quarter of 2024.
GRAND CANYON, a global pivotal cohort
in Becker: GRAND CANYON, an expansion of the CANYON placebo-controlled trial, is a multi-center, randomized, double-blind, placebo-controlled
cohort to evaluate the safety and efficacy of sevasemten in adults with Becker. The primary endpoint of GRAND CANYON is change in NSAA.
In addition, other functional assessments, biomarkers of muscle damage and safety will be assessed. GRAND CANYON is an 18-month cohort
anticipated to recruit approximately 120 individuals with Becker. Data from GRAND CANYON, if positive, could support a marketing application.
To learn more, go to clinicaltrials.gov (NCT05291091) or the GRAND CANYON microsite: https://www.beckergcstudy.com.
Duchenne Muscular Dystrophy
LYNX Phase 2 trial in boys with Duchenne:
LYNX is a 2-part multi-center, dose-finding Phase 2 trial to evaluate the effect of sevasemten on safety, PK, and biomarkers of muscle
damage in children aged 4 to 9 years with Duchenne treated with oral, once-daily sevasemten. The trial will also explore changes in functional
measures such as NSAA, stride velocity 95th centile (SV95C) and self-reported/caregiver-reported outcomes.
The Company plans to report LYNX data,
including safety, PK, changes in biomarkers of muscle damage and functional changes in NSAA and SV95C in the fourth quarter of 2024.
The Company will rely on LYNX data, along with data from the FOX trial of Duchenne children previously
treated with gene therapy, to guide the design and powering of a Phase 3 trial in Duchenne, planned to be initiated in the first
half of 2025. For more information on LYNX go to clinicaltrials.gov to learn more about this trial (NCT05540860).
FOX Phase 2 trial in boys with Duchenne
(previously treated with gene therapy): The Company is advancing FOX, a Phase 2 placebo-controlled trial to assess the effect of
sevasemten over 12 weeks on safety, PK and biomarkers of muscle damage in children and adolescents aged 6 to 14 years with Duchenne who
have been previously treated with gene therapy. The trial will also explore changes in functional measures such as NSAA, SV95C and self-reported/caregiver-reported
outcomes. There has been exceptional enthusiasm from the Duchenne community for this trial, evident in the Company’s ability to
over-enroll the trial within two months. Go to clinicaltrials.gov to learn more about this trial (NCT06100887).
Strengthened Engagement with the
Scientific and Patient Communities
The Company continued its education
and outreach in the HCM and muscular dystrophy medical and patient communities. Presentations were made at the American Heart Association’s
Basic Cardiovascular Sciences Scientific Sessions and Parent Project Muscular Dystrophy Annual Conference, as well as additional patient-focused
forums. The Company continues to sponsor and participate in numerous other clinician and patient-focused events.
Second Quarter Financial Results
Cash, cash equivalents and marketable
securities were $511.8 million as of June 30, 2024.
Research and development (R&D)
expenses were $30.7 million for the second quarter of 2024, compared to $27.7 million for the immediately preceding quarter. The
increase of $3.0 million was primarily driven by an additional $1.7 million in clinical trial expenses and related development activities
for the sevasemten and EDG-7500 clinical programs from increasing clinical trial enrollment, $0.9 million increase in drug discovery
and preclinical costs, and $0.4 million higher personnel-related costs.
General and Administrative (G&A)
expenses were $7.4 million for the second quarter of 2024, compared to $7.1 million for the immediately preceding quarter. The increase
of $0.3 million was primarily driven by $0.2 million in increased personnel-related costs and $0.1 million in professional and consulting
costs.
Net loss and net loss per share for
the second quarter of 2024 was $31.5 million or $0.34 per share, compared to $28.5 million or $0.33 per share for the immediately preceding
quarter.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle
disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal
myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator
for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development.
The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases.
To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook and Instagram.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements
include, among other things, statements regarding the potential of, and expectations regarding, Edgewise’s product candidates and
programs, including sevasemten and EDG-7500; statements regarding Edgewise’s expectations relating to its clinical trials, including
timing of reporting data (including the CANYON Phase 2 trial, LYNX Phase 2 trial, the single dose arm of CIRRUS-HCM in patients with
obstructive HCM and the topline data of Phase 1 trial of EDG-7500 in healthy volunteers) and statements regarding Edgewise’s expectations
relating to its plans to investigate fixed-dose regimens of EDG-7500; statements regarding the advancement of Edgewise’s research
and development programs; the timing of the initiation of a Phase 3 trial of sevasemten in Duchenne, a 28-day trial in patients with
obstructive and non-obstructive HCM and an open-label extension trial of EDG-7500; the possibility of data from GRAND CANYON to support
a marketing application; statements regarding Edgewise’s pipeline of product candidates and programs; statements regarding Edgewise’s
anticipated milestones; statements regarding potential over enrollment of the FOX Phase 2 trial; and statements by Edgewise’s President
and Chief Executive Officer. Words such as “believes,” “anticipates,” “plans,” “expects,”
“intends,” “will,” “goal,” “potential” and similar expressions are intended to identify
forward-looking statements. The forward-looking statements contained herein are based upon Edgewise’s current expectations and
involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected
in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise’s
limited operating history, its products being early in development and not having products approved for commercial sale; risks associated
with Edgewise not having generated any revenue to date; Edgewise’s ability to achieve objectives relating to the discovery, development
and commercialization of its product candidates, if approved; Edgewise’s need for substantial additional capital to finance its
operations; Edgewise’s substantial dependence on the success of its sevasemten; Edgewise’s ability to develop and commercialize
sevasemten and EDG-7500 and discover, develop and commercialize product candidates in future programs; risks related to Edgewise’s
clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise’s product candidates
causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials
not being predictive of the success of later clinical trials and the risks related to the results of Edgewise’s clinical trials
not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in
clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks
relating to interim, topline and preliminary data from Edgewise’s clinical trials changing as more patient data becomes available;
risks related to the regulatory approval processes being lengthy, time consuming and inherently unpredictable; risks related to regulatory
authorities not accepting data from trials conducted in locations outside of their jurisdiction; risks relating to Edgewise’s ability
to attract and retain highly skilled executive officers and employees; Edgewise’s ability to obtain and maintain intellectual property
protection for its product candidates; Edgewise’s reliance on third parties; general economic and market conditions; and other
risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents
that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as
of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the forward-looking statements, except as required by law.
This press release contains hyperlinks
to information that is not deemed to be incorporated by reference into this press release.
Edgewise
Therapeutics, Inc.
Condensed
Statement of Operations
(in
thousands except share and per share amounts, unaudited)
| |
Three
months ended | |
| |
June
30, 2024 | | |
March
31, 2024 | |
Operating expenses: | |
| | | |
| | |
Research and development | |
$ | 30,680 | | |
$ | 27,694 | |
General
and administrative | |
| 7,427 | | |
| 7,059 | |
Total
operating expenses | |
| 38,107 | | |
| 34,753 | |
Loss from
operations | |
| (38,107 | ) | |
| (34,753 | ) |
Interest income | |
| 6,610 | | |
| 6,228 | |
Net
loss | |
$ | (31,497 | ) | |
$ | (28,525 | ) |
Net loss per share - basic and
diluted | |
$ | (0.34 | ) | |
$ | (0.33 | ) |
Weighted-average
shares outstanding, basic and diluted | |
| 93,515,356 | | |
| 87,567,307 | |
Edgewise
Therapeutics, Inc.
Condensed
Balance Sheet Data
(in
thousands, unaudited)
| |
June
30, | | |
December
31, | |
| |
2024 | | |
2023 | |
Assets | |
| | | |
| | |
Cash, cash equivalents
and marketable securities | |
$ | 511,751 | | |
$ | 318,393 | |
Other assets | |
| 19,896 | | |
| 21,642 | |
Total assets | |
$ | 531,647 | | |
$ | 340,035 | |
Liabilities and stockholders'
equity | |
| | | |
| | |
Liabilities | |
| 21,173 | | |
| 21,205 | |
Stockholders'
equity | |
| 510,474 | | |
| 318,830 | |
Total liabilities
and stockholders' equity | |
$ | 531,647 | | |
$ | 340,035 | |
###
Edgewise
Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Aug 2023 to Aug 2024